UniQure/CSL Set To Launch First Hemophilia B Gene Therapy Next Year At Record Price

With $3.5m Price Tag

The firms’ gene therapy Hemgenix has won a US thumbs up for the treatment of hemophilia B and plans are underway for a US launch with a big price tag that experts agree should pay off in the long-term.  

Hands woman hold drop of blood on blue background.
Hemophilia B Is A Rare Clotting Disorder That Mostly Affects Males • Source: Shutterstock

uniQure N.V./CSL Limited’s Hemgenix (tranacogene dezaparvovec-drlb) has been approved for the treatment of adults with moderately severe to severe hemophilia B by the US Food and Drug Administration, making it the first gene therapy for the rare bleeding disorder and the most expensive drug to date.

The Australian firm revealed the treatment would cost $3.5m in the US, edging past the $3m price tag for

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip